Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension
- Status
- COMPLETED
- Phase
- PHASE3
Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)
- Status
- WITHDRAWN
- Phase
- PHASE2
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
- Status
- COMPLETED
- Phase
- PHASE1
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of KBA1412 in Participants With Advanced Solid Malignant Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
AK112 in Advanced Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
- Status
- RECRUITING
- Phase
- PHASE2